Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers

Corporate Breaking News

Home : Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers

Jul 14 2020	Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers
CAMBRIDGE, Mass., July 14, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it has entered into a global collaboration with Roche and...


Source:https://www.prnewswire.com:443/news-releases/blueprint-medicines-announces-global-collaboration-with-roche-to-develop-and-commercialize-pralsetinib-for-patients-with-ret-altered-cancers-301092613.html

Related News
» Anglo-Norwegian EXACT Therapeutics Raises NOK 155 Million and Lists on Oslo Stock Exchange's Merkur Market » OTC Markets Group nimeää Arctic Securities LLC:n an OTCQX-sponsoriksi